<DOC>
	<DOCNO>NCT02014129</DOCNO>
	<brief_summary>The main purpose study evaluate safety side effect LY2835219 Japanese participant advance cancer .</brief_summary>
	<brief_title>A Study LY2835219 Japanese Participants With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Have histological cytological evidence diagnosis cancer ( either solid tumor lymphoma ) advance and/or metastatic Must , judgment investigator , appropriate candidate experimental therapy available standard therapy fail provide clinical benefit disease Have presence measurable nonmeasurable disease define Response Evaluation Criteria Solid Tumors Guideline Version 1.1 , Revised Response Criteria Malignant Lymphoma Guideline Have adequate organ function Have discontinue previous therapy cancer , include chemotherapy , radiotherapy , immunotherapy , investigational therapy , least 21 day first dose study drug recover acute effect therapy Males must agree use medically approve barrier contraceptive precaution study 3 month follow last dose study drug Females child bear potential : must agree use medically approve contraceptive precaution study 3 month follow last dose study drug , must negative serum urine pregnancy test ≤7 day first dose study drug . A breastfeed woman must breastfeed . If female stop breastfeed enters study , female must stop breastfeeding day first study drug administration least 3 month last administration Have estimate life expectancy ≥12 week Are able swallow capsule Have receive treatment within 21 day initial dose study drug experimental agent noncancer indication receive regulatory approval indication Have medical history follow condition : presyncope syncope either unexplained cardiovascular etiology , ventricular arrhythmia ( e.g. , ventricular tachycardia ventricular fibrillation ) sudden cardiac arrest Have baseline follow finding screen electrocardiogram ( ECG ) : ventricular tachycardia , ventricular fibrillation , abnormal QTc use Bazett 's formula ( QTcB ) ( define ≥470 millisecond ) , evidence acute myocardial ischemia Have serious preexist medical condition , judgment investigator , would preclude participation study ( example , history major surgical resection involve stomach small bowel ) Have symptomatic central nervous system ( CNS ) malignancy metastasis . For asymptomatic participant without history CNS malignancy metastasis Have evidence history leukemia Have receive stemcell transplant . As exception , participant lymphoma receive autologous stemcell transplant eligible study , 75 day pass initial dose study drug Have active bacterial , fungal , and/or know viral infection ( example , human immunodeficiency virus [ HIV ] , hepatitis B , hepatitis C )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>